Infection Prevention, Epidemiology and Antimicrobial Stewardship, Detroit Medical Center and Wayne State University, Detroit, MI 48201, USA.
J Hosp Med. 2012;7 Suppl 1:S13-21. doi: 10.1002/jhm.983.
Increasing numbers of serious hospital/healthcare- or community-acquired infections are caused by resistant (often multi-drug resistant) bacterial pathogens. Because delayed or ineffective initial therapy can have severe negative consequences, patients at risk for these types of infections typically receive initial empiric antibiotic therapy with a broad-spectrum regimen covering the most likely pathogens, based on local surveillance data and risk factors for infection with a resistant microorganism. While improving the likelihood of a successful outcome, use of broad-spectrum, often high-dose, empiric antimicrobial therapy also creates pressure for the selection or development of resistant microorganisms, as well as increasing costs and possibly exposing patients to adverse events or collateral damage such as Clostridium difficile-associated disease. De-escalation is a strategy that attempts to balance the competing aims of providing initial empiric therapy that is appropriate and covers the likely pathogens, and limiting antimicrobial exposure and increased risk for emergence of resistant pathogens. More specifically, the de-escalation strategy involves collection of cultures for later microbiological assessment before initiating broad-spectrum empiric therapy covering the most likely pathogens, with the intention of streamlining or de-escalating to a more narrow-spectrum antimicrobial regimen 2-3 days later if warranted by clinical status and culture results. In some cases, negative culture results and subsequent clinical review may allow for termination of initial empiric therapy. In this manner, de-escalation enables more effective targeting of the causative pathogen(s), elimination of redundant therapy, a decrease in antimicrobial pressure for emergence of resistance, and cost savings. This article examines application of the de-escalation strategy to 3 case patients, one with healthcare-associated pneumonia, another with complicated intra-abdominal infection, and a third with central line-associated bacteremia. Journal of Hospital Medicine 2012;7:S13-S21. © 2012 Society of Hospital Medicine.
越来越多的严重医院/医疗保健或社区获得性感染是由耐药(通常是多药耐药)细菌病原体引起的。由于延迟或无效的初始治疗可能会产生严重的负面后果,因此,有这些类型感染风险的患者通常会根据当地监测数据和感染耐药微生物的危险因素,使用广谱方案进行初始经验性抗生素治疗,覆盖最可能的病原体。虽然使用广谱、通常高剂量的经验性抗菌治疗提高了成功治疗的可能性,但也为耐药微生物的选择或发展创造了压力,同时增加了成本,并可能使患者面临不良事件或附带损害,如艰难梭菌相关性疾病。降级是一种试图平衡提供适当的初始经验性治疗并覆盖可能病原体的目标,同时限制抗菌药物暴露和增加耐药病原体出现风险的策略。更具体地说,降级策略包括在开始覆盖最可能病原体的广谱经验性治疗之前采集培养物进行后期微生物学评估,如果临床状况和培养结果需要,意图在 2-3 天后将治疗方案简化或降级为更窄谱的抗菌药物。在某些情况下,阴性培养结果和随后的临床审查可能允许终止初始经验性治疗。通过这种方式,降级使针对致病病原体的治疗更加有效,消除了冗余治疗,减少了耐药出现的抗菌压力,并节省了成本。本文通过 3 个病例患者来检验降级策略的应用,其中一个是医院获得性肺炎,另一个是复杂性腹腔内感染,第三个是中心静脉相关菌血症。医院医学杂志 2012;7:S13-S21。©2012 年医院医学学会。